|
2,4-Diamino-5-(3,4,5-Trimethoxy-Benzyl)-Pyrimidin-1-Ium
|
DB03125 |
|
|
Arsenous acid
|
DB04456 |
|
|
Irofulven
|
DB05786 |
[A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track” status by the U.S. Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers.
MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.] |
|
LGD-1550
|
DB05785 |
[LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.] |
|
4-O-(4,6-Dideoxy-4-{[4-[(4-O-Hexopyranosylhexopyranosyl)Oxy]-5,6-Dihydroxy-3-(Hydroxymethyl)Cyclohex-2-En-1-Yl]Amino}Hexopyranosyl)Hexopyranose
|
DB04453 |
|
|
Alpha-Aminobutyric Acid
|
DB04454 |
|
|
Tetrabromo-2-Benzotriazole
|
DB04462 |
|
|
Serelaxin
|
DB05794 |
[Recombinant human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic bones come together).It is a heterodimer protein secreted by the corpus luteum and placenta during pregnancy.] |
|
PRO-542
|
DB05793 |
[PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates. ] |
|
3-(2-Benzothiazolylthio)-1-Propanesulfonic Acid
|
DB03132 |
|
|
3-(4-Amino-1-Tert-Butyl-1h-Pyrazolo[3,4-D]Pyrimidin-3-Yl)Phenol
|
DB04463 |
|
|
Arylacenamide
|
DB05792 |
[Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.] |
|
(C8-S)-Hydantocidin 5'-Phosphate
|
DB04460 |
|
|
S-P-Nitrobenzyloxycarbonylglutathione
|
DB03130 |
|
|
Coproporphyrinogen III
|
DB04461 |
|
|
Perflubron
|
DB05791 |
[Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.] |
|
SR 140333
|
DB05790 |
[SR 140333 is tachykinin antagonist which has potential to treat diarrhoea due to food allergy or inflammatory bowel disease.
] |
|
Transfluthrin
|
DB15117 |
[Transfluthrin is under investigation in clinical trial NCT02394522 (Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Zambia (SR-M-ZM)).] |
|
Ramatercept
|
DB15116 |
[Ramatercept is under investigation in clinical trial NCT00952887 (A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women).] |
|
Ropeginterferon alfa-2b
|
DB15119 |
[Ropeginterferon alfa-2b is under investigation in clinical trial NCT01949805 (Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera).] |
